Our website detected that you are using a browser (Internet Explorer) that we no longer support. Please use the following browsers instead: Chrome, Firefox, Edge, or Safari.
First, a researcher meets with a participant, performs a clinical assessment, and obtains biospecimens. Participants include people with Parkinson's Disease, people without Parkinson's Disease (controls), and people with a Parkinson-like disorder (Parkinsonism).
After meeting with a patient, the researcher submits biosamples to the NINDS biorepository, and de-identified clinical data to the PDBP Data Management Resource (DMR).
Once data is in the PDBP DMR, qualified researchers can request data. The Data Acquisition Committee (DAC) reviews the request, and then grants approval. Once biospecimens are in the biorepository, qualified researchers can request access to biosamples. The Parkinson's Disease Biosample Resource Acquisition Committee (PD BRAC) reviews the request and then grants approval.
Researchers find biomarkers that will significantly improve clinical trial design and outcomes for Parkinson's disease and related disorders.